Atezolizumab is a programmed death ligand 1 (PD-L1)-targeting monoclonal antibody approved as first-line treatment for non-small cell lung cancer (NSCLC), among other solid tumor indications. This evidence concerns the gene CD274 and non-small cell lung carcinoma.